



Rett Syndrome Europe Activity Report

2012 - 2013



RSE Board members (2013)



Martine Gaudy



Lorna Jaffa



Danijela Szili



Oliviero Dell'Oro



Thomas Bertrand



RSE aims

- **AIM 1 of the statutes:** To make Rett syndrome better known to the public, professionals, carers and those who are directly concerned in all European countries
- **AIM 2:** To improve the communication within the European Rett Community
- **AIM 3:** To promote as a representative European organisation, the interests of people with RTT and families
- **AIM 4:** To Expand RSE to all European Countries and to assist, if necessary, in the creation of national associations
- **AIM 5:** To promote research into Rett syndrome

Building the Network

- **AIM 1 of the statutes:** To make Rett syndrome better known to the public, professionals, carers [...]

1. Revitalise the network

Constant update of all the contacts in all countries to be able to communicate

2. Inform, advertise special events

News/Articles/Events on RSE website

Video of associations during last GA

Building the Network

- **AIM 1 of the statutes:** To make Rett syndrome better known to the public, professionals, carers [...]

Ms. Glòria Renom

Member of the Parliament of Catalonia

Mr. Thomas Bertrand

President of Rett Syndrome Europe

Dr. Josep Torrent

CEO of the foundation Dr. Robert

Dr. Roser Valles

Advisor to the Office of the Ministry of Health

Ms. Monica Martinez

Chief of the Teknon Foundation

Dr. Jose MaPayà

Medical Director of the Medical Center Teknon

Mr. Jordi Serra

President of the Catalan Association of Rett Syndrome

Mr. D. Juan José García Fenoll

President of the Spanish Association of Rett Syndrome

On March 2, 2013 took place the 3rd Catalan Rett Syndrome Day:
“Update on Research, Emotional Wellness, Disability and
Guardianship at the Teknon Medical Center in Barcelona”



Building the Network

rse rett syndrome europe

Home Rett Syndrome RSE association Research Contact Conferences Events Projects

The Drug Information Association (DIA) 2013 Eurometing

by T.Bertrand on 14 APRIL 2013 in CONFERENCES, EVENTS, NEWS

By Danijela Szili. The DIA (Drug Information Association) is a global-wide working association which provides networking opportunities and information about innovation in science and pharmacy by organising events and training courses over the entire world. The biggest get-together on our continent this year was the Euromeeting 2013 (March 6th RAI centre, Amsterdam) with more than 3,000 participants. [...]

READ FULL STORY • COMMENTS ARE CLOSED

3rd European Rett Syndrome Conference "Research Update and Preventive Management"

by T.Bertrand on 27 MARCH 2013 in CONFERENCES, EVENTS

The 3rd European Rett Syndrome Conference Maastricht, "Research Update & Preventive Management" (ERSCM 2013), will take place on October 17th – 19th, 2013 at the MECC in Maastricht, The Netherlands. For more information on registration and program please visit: <http://www.rscm.eu> ERSCM 2013 is an initiative of the GKC (Gouverneur Kremers Centrum), Stichting Terre (Dutch Rett Syndrome Foundation) and NRSV (Dutch Rett Syndrome Association) and [...]

READ FULL STORY • COMMENTS ARE CLOSED

<http://rettsyndrome.eu>

rse rett syndrome europe

Home Rett Syndrome RSE association Research Contact Conferences Events Projects

Radiure Désactiver pour : finnois Options ▾

01/01/13 | Retin oirehytymä

Aure.fi sivustolle on avattu uusi keskustelualue. Keskustelualueelle pääsee klikkaamalla yläpalkissa olevaa Keskustelu -linkkiä. Forumille pitää kirjautua, jotta pystyt kirjoittamaan ja vastaanottamaan viestteihin. Ulkousa ja rakenne on vielä hieman kesken, mutten forumi toimi normalisti. Tervetuloa keskustelemaan ja jakamaan ajatuksia! Hyvää Uutta Vuotta!

European Rett Syndrome Congress 17 lokakuu

Katso kaikki tapahtumat

Vilmeissä Kommentit

Syksyn tapahtumat | AURE: Tapahtumat

Marjo: Keskustelu

päivi sippu: Keskustelu

© 2013 AURE

rse General Assembly November 17, LONDON

VISIT US ON FACEBOOK

Rett Syndrome Europe Vous aimez.

EUROPEAN EVENTS

ADVERT

JOIN RareConnect A PARTNERSHIP OF EUROSIS AND NORD

© 2013 Rett Syndrome Europe. All Rights Reserved.

Rett Syndrome Research Trust Blog Rett Syndrome News Rett Syndrome Europe Rett UK

Life with Rett Syndrome – A Lost Friend Rett Syndrome Awareness

Boys With Rett Give Us Clues About MeCP2's Function Special Successes over Autism: Autism

Rett Syndrome Connection

Rett Researchers Get Up Close and Personal New Rett Video Channel

FUNDING RESEARCH – FUNDING RESULTS: RECORD \$4.2 MILLION AWARDED Clinical trial for Rett syndrome launched

"Cleaning Up Science"

Rett Syndrome Video Channel: The Premier Place for Rett Syndrome Videos

visit us on facebook!

The Drug Information Association (DIA) 2013 Eurometing


3rd European Rett Syndrome Conference "Research Update and Preventive Management"

Re: UK Family Weekend

Re: UK's first ever blog, to celebrate me! Melanie Ekless, Chief Executive,

<http://aure.fi>

Website stats



Building the Network

- **AIM 2:** To improve the communication within the European Rett Community

→ **Discuss with other European parents and other Rare Diseases communities**

RareConnect (June 2012)

Facebook (March 2013)

Building the Network

des personnes, des lieux ou d'autres choses Accueil Retrouver des amis  

Maintenant Inscription sur Facebook.

Administration Notifications Modifier la Page Développer l'Audience Aide Afficher

rse
rett syndrome europe

Rett Syndrome Europe 301 j'aime - 3 personnes en partage

Organisation à but non lucratif
Is a network of National Rett Associations which promotes research and aims to improve the quality of life of all individuals with Rett syndrome in Europe.

A propos

À la une

5 amis Rett Syndrome Europe

Conférence européenne sur le syndrome de Rett 2013

Partenaires et

stellaapeckary | publié il y a environ 1 mois | Rédigé à l'origine en allemand

Leider konnte ich keine Verbindung mit dem link zu Dr. Kauffman bekommen. Ich nehme jedoch an, dass das Präparat - und der Versuch ist ja nur für die USA gültig - via Placebo versus IGF 1 Studie gemacht... (Afficher plus)

Demande de la traduction humaine de qualité (ce message seulement)
Modifier | Mettre hors ligne | réponse

danieljelasilli | publié il y a environ 1 mois | Rédigé à l'origine en anglais

It is all about assessing benefit/risk ratio. If FDA concludes after evaluating the results of this Clinical Trial that the benefits are higher than the risk (the adverse drug reactions), then the medicinal... (Afficher plus)

Demande de la traduction humaine de qualité (ce message seulement)
Modifier | Mettre hors ligne

pinivg | publié il y a 2 mois | Rédigé à l'origine en italien

Anche a Viareggio (Italia) è in corso una sperimentazione con IGF1 nella sindrome di Rett. Se desideri ulteriori informazioni puoi scrivermi: g.pini@usl12.toscana.it

Demande de la traduction humaine de qualité (ce message seulement)
Modifier | Mettre hors ligne

martacampabadal | publié il y a 3 mois | Rédigé à l'origine en anglais

Clinical trial: Treatment of Rett Syndrome With Recombinant Human IGF-1
Investigators are recruiting children for a clinical trial using the medication recombinant human IGF-1 (a.k.a. mecabolin or INCRELEX) to see if it improves the health of children with Rett syndrome (RTT). While IGF-1 is approved by the Food & Drug Administration (FDA) for certain use in children, it is considered an investigational drug in this trial because it has not previously been used to treat Rett. Information from this study will help determine if IGF-1 effectively treats Rett but will... (Afficher plus)

Traduire en français:
Traduction instantanée de cette conversation (Google Translate)
Demande de la traduction humaine de qualité (ce message seulement)

Aucun signalement | Mettre hors ligne | Rendre privé | Supprimer | Modifier | réponse

BIENVENUE THOMASBERTRANDRETT | PROFIL | DÉCONNEXION

Communauté: Le syndrome de Rett

Communautés de malades atteints de maladies rares Langue: Français

ULZIBAT - Méthode sujet public il y a environ 20 heures Voir la transcription

Statins improve symptoms of Rett syndrome in mice réponse publiée il y a 4 jours Voir la transcription

L'huile de poisson comme "traitement" pour le syndrome de Rett document publié il y a 22 jours Voir la transcription

Phase II Study of EPI-743 for Treatment of Rett Syndrome in Italy sujet public il y a environ 1 mois Voir la transcription

Clinical trial: Treatment of Rett Syndrome With Recombinant Human IGF-1 réponse publiée il y a environ 1 mois Voir la transcription

Life with Rett Syndrome: It is so much more than the facts, the stats and the science sujet public il y a environ 1 mois Voir la transcription

Life with Rett Syndrome réponse publiée il y a environ 1 mois Voir la transcription

<https://www.rareconnect.org/en/community/rett-syndrome>



Facebook statistics

Trouvez des personnes, des lieux ou d'autres choses

Accueil Retrouver des amis Publier

Vous publiez, commentez et indiquez que vous aimez en tant que Rett Syndrome Europe — Changer à Thomas Bertrand

Rett Syndrome Europe Mentions J'aime ▾ ✓ J'aime

Mentions J'aime et personnes qui en parlent

Personnes qui en parlent Total des mentions J'aime

6 471

Statistiques des Pages

24 mars 2013 Semaine la plus populaire [?]

35-44 ans Tranche d'âge la plus populaire [?]

Personnes qui en parlent Nouveaux J'aime par semaine

Sep 12, 2013 Oct 11, 2013

Ami(e)s qui aiment Rett Syndrome Europe

À propos de Crée une publicité Crée une Page Développeurs Emplois Confidentialité Cookies Conditions d'utilisation Aide

Facebook © 2013 · Français (France)

Promouvoir la page

Votre publicité

EURORDIS is a non-governmental patient-driven

EURORDIS Membership Meeting 2013 and DITA Task Force meeting in Dubrovnik | Rett Syndrome Europe <http://www.rettsyndrome.eu/news/conferences/eurodis-membership-meeting-2013-and-dita-task-force-meeting-in-dubrovnik/>

Stimuler la publication

Date	Personnes qui en parlent	Nouveaux J'aime par semaine
Sep 12, 2013	6	~10
Sep 19, 2013	~10	~15
Sep 26, 2013	~15	~20
Oct 03, 2013	~20	~25
Oct 10, 2013	~35	~30
Oct 11, 2013	~30	~25

RareConnect statistics (since June 2012)

RSE Moderators: Danijela Szili, Stella Peckary, Thomas Bertrand

- Since its creation the Rett Syndrome community has:
 - **190** members
 - **22** patient groups featured
 - **16** articles
 - **12** testimonials
 - **50** forum topics
 - **6** Documents
- **Who has visited the Rett Syndrome Community since its creation?**
 - **7057** unique visitors
- **Where are visitors coming from?**

Top 10 countries with most visitors:

• 1.	United States	1,726
• 2.	Italy	683
• 3.	France	572
• 4.	United Kingdom	487
• 5.	Germany	477
• 6.	Spain	432
• 7.	Canada	224
• 8.	Australia	204
• 9.	Mexico	176
• 10.	Netherlands	119
- **How are people finding the community on search engines?**

Top 10 keywords (the words people use on a search engine to find the community):

 - mi princesa rett
 - rareconnect
 - sindrome di rett
 - rett syndrom
 - ipad apps for rett syndrome
 - syndrome de rett
 - ulzibat
 - sindrome de rett
 - rett syndrome apps
 - 3rd european rett syndrome congress
- **How did visitors find the community?**
 - 1.google 3,381
 - 2.(direct) 1,370
 - 3.facebook.com 901
 - 4.m.facebook.com 410
 - 5.rettsyndrome.eu 269
 - 6.europdis.org 226
 - 7.bing 91
 - 8.twitter.com 89

External Influence and Advocacy

- **AIM 3:** To promote as a representative European organisation, the interests of people with RTT and families
 - *Having RSE officially in the network of European institutions*
1. **RSE is a member of EURORDIS:** Allows RSE to vote at the GA of EURORDIS During the EMM (EURORDIS Membership Meetings), *Martine and Danijela in Dubrovnik (June 2013)*
 - *EURORDIS fellowship was granted for Hungary, Croatia and neighbouring countries to attend this EMM*
 - *RSE was granted funds in EURORDIS “Support Rare Disease Federations” 2013 call for Eastern European countries to be able to attend today’s RSE General Assembly*

External Influence and Advocacy

Rare Diseases: an EU Public Health Priority

Improving access to quality care

Improving acces to Orphan Drugs

Deal with ethical issues



Promote Research and link patients to professionals acrosss country borders



External Influence and Advocacy

2. EURORDIS Training resources:

- Summer School June on « patient advocates in clinical trials and drug development » June 2013, Barcelona, *Liana Murtazina (Russia)*
- Online learning tools
 - clinical trial and orphan medicinal products

3. EURORDIS Task Force:

- DITA Drug Information and Transparency Access Task Force June 2013, Dubrovnik, *Danijela*

4. EUKERD: European Union Committee of Experts in Rare Diseases – *Gérard Nguyen*

External Influence and Advocacy

5. EMA European Medicine Agency (London, UK): RSE fulfils the criteria to be involved (letter of 14/11/11)

- Training programs for patients and patients advocates: Pharmacovigilance Workshop, *Danijela*
- PCWP: Patient and Consumer Working Group, *Danijela (Training Sessions)*
 - *RSE applied to the Call for expression of interest to eligible organisations to become a member of the PCWP – not granted 2013-2016*
- PDCO: Paediatric Committee
 - *New call for PDCO members from Academia / Health Care / Patient Representatives – deadline 8 November*

External Influence and Advocacy



Danijela Szili
(President of the Hungarian Rett Syndrome Foundation)

DITA member (Drug Information, Transparency and Access)

EUPATI European Patients' Academy on Therapeutic Innovation

25TH ANNUAL EUROMEETING AMSTERDAM 2013
4-6 March 2013 RAI, Amsterdam, Netherlands

Final Programme DIA www.diauh.org

6TH ANNUAL CLINICAL FORUM THE HAGUE 2012
The Empowered Patient
8-10 October 2012 World Forum | The Hague, The Netherlands

Rett Syndrome Europe (www.rettsyndrome.eu) is a network of National Rett Associations which promotes research and aims to improve the quality of life of all individuals living with Rett syndrome in Europe. RSE is a member of Eurodis and RareConnect and one of the eligible patients' & consumers' organisations at the EMA.

Rett Syndrome
Rett syndrome is a rare, genetic neurodevelopmental disorder which causes lifelong multiple disability almost exclusively in females.
A large proportion of patients with Rett syndrome have a mutation, or deletion, on the MeCP2 gene on the X chromosome.
With rare exceptions it is caused by de novo mutation in a sperm cell.
The incidence is estimated at 1 in 24,000 (i.e. 1 in 12,000 girls born).

Symptoms Include:
Loss of purposeful hand control
Functional hand use replaced by compulsive hand movements
Breathing abnormalities
Severe seizures
Orthopedic abnormalities including scoliosis and osteoporosis
Disrupted sleep patterns
Extreme anxiety
Seizures
Impaired cardiac and circulatory function
Parkinsonian tremor
Immunodeficiency
Growth impairment

Reversibility and potential therapies
It has been shown that many of the features of Rett are reversible in mice, and that these features are probably due to dysfunction of neurons and supporting cells, rather than neural degeneration.
These findings suggest that some and perhaps most symptoms can be reversed in affected individuals if effective therapies that can overcome the consequences of loss of function or dysfunction of MeCP2 are discovered.

Therapeutic Targets
MECP2+ Target
Activating Sustained MeCP2 on inactive X Chromosome
Read-through Gene Therapy for MeCP2 Exon 3 skipping
(approximately one-third of Rett syndrome patients have "nonsense" mutations)
Pharmacological Chaperones (potentially in the cases where a "missense" mutation is caused by MeCP2 protein misfolding)
Gene Therapy
Protein Replacement

Downstream Targets
Growth Factors (BDNF, Igf1)
Catecholamine Receptor Agonists (increasing norepinephrine (noradrenergic), serotonin, dopamine), MAO inhibitors, Reuptake Inhibitors, Receptor agonists

Immune System
Bone marrow transplantation

Rett Syndrome Network Database (www.rettdatabasenetwork.org)
This European Database has been established to share clinical and genetic information.
It contains information on 2000 patients from 13 countries and can expand indefinitely.
It should serve for the recruitment of patients into clinical trials and for developing quality measures to drive up standards of medical management.

External Influence and Advocacy

6. DIA: Drug Information Association: Annual Euromeeting March 2013, Amsterdam, *Danijela*

- *RSE applied for a DIA Philanthropy Grant Application for the translation of a book to be published by AFSR – Not granted*

7. EUPATI: European Patients Academy on Therapeutic Innovation: Workshop April 2013, Roma, *Olga Timutsa (Russia)*

Our Network

- **AIM 4:** To Expand RSE to all European Countries and to assist, if necessary, in the creation of national associations
 1. Russia
 2. Greece
 3. Romania
 4. Iceland
 5. Macedonia (contacts)
 6. Bulgaria (contacts)

→39 contacts

AIM 5: To promote research into Rett syndrome

The screenshot shows the homepage of the Rett Database Network. At the top, there are logos for EuroRETT (European Network on Rett Syndrome) and RETTSEARCH. Below the header, there are links for "ABOUT THIS PROJECT", "HOW TO JOIN", "ACCESS RULES", "GUIDELINES", and "INFORMED CONSENT FORM". Underneath these, there are links for "Login" and "Back to Homepage". A "Back to Patient List" link is also present. The main content area displays the number of patients in the archive (1904) and a table of patient counts by country:

Country	Number of Patients
Australia	1
Czech Republic	0
Germany	0
Denmark	64
Spain	387
Finland	0
France	252
United Kingdom	255
Croatia	29
Hungary	58
Israel	93
India	3
Italy	601
Poland	0
Portugal	0
Romania	15
Serbia	50
Russia	0
USA	96

<http://www.retdatabasenetwork.org>

Oliviero Dell'Oro (Italy)
Jordi Serra (Catalonia)



«The aim of this project is to connect the already existing databases and to create a unified repository [...] The data will be accessible to the participants and to the scientific community according to rules that assure transparency and equity [...] This international effort will be of great value in order to perform genotype-phenotype correlations, to study modifier genes, and to select subgroups of patients for clinical trials.»

Challenges and questions

- We now have the Network (we can still improve)
- We now have tools to advertise (Website)
- We have tools to communicate (Rareconnect/
facebook)
 - need for others? (twitter) – time consuming
- What's next: how can we use the network with
the tools?
- New RSE Roles? Fundraising? For What? How?
 - (Role in advocating for research and/or care issues?)